Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

IL-33 (human), (recombinant) (His-tag)

 
ALX-201-350-C010 10 µg 245.00 USD
Do you need bulk/larger quantities?
 

Product Specification

Alternative Name:Interleukin-33, NF-HEV, IL-1F11
 
Source:Produced in E. coli. Recombinant human IL-33 (aa 112-270) is fused at the C-terminus to a His-tag.
 
UniProt ID:O95760
 
Concentration:1mg/ml
 
Formulation:Liquid. 0.2µm-filtered solution in 55mM TRIS-Cl, pH 8.2, containing 150mM sodium chloride.
 
Purity:≥90% (SDS-PAGE)
 
Endotoxin Content:<1.0EU/µg protein (LAL-test).
 
Specificity:Binds to human ST2.
 
Biological Activity:Activates ST2-dependent NF-κB pathway.
 
Shipping:Shipped on Blue Ice
 
Long Term Storage:-20°C
 
Use/Stability:Working aliquots are stable for up to 3 months when stored at -20°C.
 
Handling:Avoid freeze/thaw cycles. After opening, prepare aliquots and store at -20°C.
 
201-350 sds
Figure 1: SDS-PAGE of IL-33 (human) (rec) (His) (Prod. No. ALX-201-350).
201-350 1
Figure 2: Binding of human IL-33 to hST2-transfected cells in cell ELISA assay.Method: HEK-293 cells were transiently transfected by lipofectamine 2000 with 200ng of human ST2-containing vector or empty vector in 96-well roundbottom plate. At 40 hours after transfection, 500ng/ml of IL-33 (human) (recombinant) (His) (Prod. No. ALX-201-350) were treated for 2 hours at RT. Cells were treated with an anti-His antibody biotin-conjugate and followed by the binding of streptavidin-HRP. To measure binding activity, 100µl of TMB substrate was added. The reaction was stopped after 15 min. by addition of 100µl of stop solution.
201-350 2
Figure 3: Activation of a human ST2-dependent NF-κB pathway using IL-33. Method: HEK 293 cells were transiently co-transfected with 500ng of human ST2-containing vector (or empty vector as a negative control), a vector containing NF-κB-driven firefly luciferase, and a vector containing Renilla luciferase as a internal control in 12-well plate. At 40 hours after transfection, cells were treated with IL-33 (human) (recombinant) (His) (Prod. No. ALX-201-350) at the concentration as indicated for 8 hours, followed by measurement of dual luciferase assay.
201-367
Figure 2:a) Pull down assay of IL-33 (human) (His) (Prod. No. ALX-201-350) by ST2 (human):Fc (human) (rec.) (Prod. No. ALX-201-367).b) Pull down assay of ST2 (human):Fc (human) (rec.) by IL-33 (human) (His). Method: 5µg of ST2 (human):Fc (human) (rec.) (or control Fc protein), 2µg of IL-33 (human) (His) (or control His protein), and protein G resin (or anti-His resin) were incubated in 0.5ml RIPA buffer overnight at 4°C. The precipitates were separated by SDS-PAGE, electro-transferred onto NC membrane, and immunoblotted for the presence of IL-33 (human) (His) or ST2 (human):Fc (human) (rec.) with anti-His HRP or anti-human IgG HRP, respectively.
Please mouse over
201-350 sds 201-350 1 201-350 2 201-367

Product Toolbox

PRODUCT RESOURCES

Datasheet
MSDS
Certificate of Analysis

RELATED PRODUCTS

By target:
IL-33
By biological activity:
IL-33 Recombinant protein
By catalog section:

PRODUCT SUPPORT

FAQs
Technical Service
Customer Service

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2017 Enzo Life Sciences, Inc.,